|
Azenosertib Clinical Trials
6 actively recruiting trials across 6 locations
▲ +1 trial since May 2026
Also known as: C29H34N8O2, KP-2638, Wee1 Inhibitor ZN-c3, ZN c3, ZN-c3 +2 more
Pipeline
Early 1: 1Phase 1: 2Phase 2: 2Phase 3: 1
Top Sponsors
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc3
- OHSU Knight Cancer Institute1
- National Cancer Institute (NCI)1
- Joyce Liu, MD1
Indications
- Cancer6
- Locally Advanced Pancreatic Ductal Adenocarcinoma1
- Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v81
- Clinical Stage III Gastric Cancer AJCC v81
- Locally Advanced Gastric Carcinoma1
Mobile, Alabama1 trial
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Site 0170-USA Mitchell Cancer Institute
Phase 2
Phoenix, Arizona1 trial
Aurora, Colorado1 trial
Phase 1
Boston, Massachusetts1 trial
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Brigham and Women's Hospital
Phase 2
Portland, Oregon1 trial
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
Early 1
Houston, Texas1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.